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Abstract
Aims: Performing percutaneous coronary intervention (PCI) to multiple coronary lesions during the same proce-
dure has potential economic and social advantages. However comprehensive outcome data of real world practice 
in a large population is limited. We aimed to compare short- and long-term outcomes between patients with multi-
vessel coronary artery disease who either underwent single- or multivessel PCI within the e-SELECT registry.
Methods and results: The e-SELECT registry combines data collected at 320 medical centres in 56 countries 
where patients received CYPHER Select® or CYPHER Select® Plus sirolimus-eluting stent (SES). Rates of myo-
cardial infarction and major adverse cardiac event (MACE) (defined as any death, myocardial infarction or target 
lesion revascularisation) were compared between patients undergoing single-vessel versus multivessel PCI. A total 
of 15,147 patients who satisfied the inclusion criteria were included in the e-SELECT registry. Two thousand two 
hundred and seventy-eight (2,278) subjects (15%) underwent multivessel PCI and 12,869 (85%) had single-vessel 
PCI. The mean age was higher in the multivessel PCI group (63 vs. 62 years, p<0.001) and there was a higher 
prevalence of diabetes mellitus (32.4 vs. 30.0%, p=0.02). Lesions were more complex in the single-PCI group 
while pre- and post-dilatation were less common in the multivessel PCI group. Myocardial infarction within the 
first 30 days post PCI was more common in the multivessel PCI group (1.9 vs. 0.8%, p<0.001) and most of the 
infarctions were periprocedural (1.3 vs. 0.6%, p=0.001). Mortality and myocardial infarction at one-year were 
higher in the multivessel PCI group resulting in a significantly higher MACE (6.1 vs. 4.6%, p=0.005).
Conclusions: Overall procedural and one year outcomes were excellent for both single- and multivessel proce-
dures. However despite lower lesion complexity, performing multivessel PCI was associated with higher rates of 
















An increasing number of patients are treated with percutaneous 
coronary intervention (PCI) and a recent analysis of revascularisa-
tion procedures from the United States demonstrated a substantial 
decrease of coronary artery bypass grafting (CABG) procedures 
compared to PCI1. The use of drug-eluting stents (DES) has dra-
matically reduced the rate of in-stent restenosis (ISR)2 and as a con-
sequence percutaneous coronary intervention can be performed in 
two or three arteries and in increasingly long and complex ather-
omatous lesions.
Performing multivessel PCI in a single sitting has potential eco-
nomic and social advantages, and most of the times the cumulative 
duration of dual antiplatelet therapy (especially after implantation 
of DES) can be shortened. Additionally, re-gaining arterial access 
for staged PCI is associated with a small but significant risk of 
access site injury and bleeding3,4.
In a recent report from the HORIZONS-AMI trial, multivessel PCI 
of the culprit lesion and bystander disease was associated with a 
higher mortality and stent thrombosis5. However, comprehensive 
outcome data of real world practice in a large population is limited.
Using data from the e-SELECT registry we aimed to compare 
outcomes in patients undergoing single vs. multivessel PCI. 
Outcomes were compared with particular reference to potential dif-
ferences in both procedural and one-year clinical outcomes.
Methods
Details of the e-SELECT registry have recently been published6. 
Briefly, e-SELECT was conducted at 320 medical centres (listed in 
an on-line supplement) in 56 countries where sirolimus-eluting 
stents (SES) have been approved for commercial use. Baseline data 
were collected between May 2006 and April 2008 in consecutive 
and eligible patients who underwent successful implantation of ≥1 
CYPHER Select® or CYPHER Select® Plus (Cordis Corporation, 
Bridgewater, NJ, USA) SES according to standard clinical practice 
and procedural techniques.
The protocol specified very few inclusion or exclusion criteria. 
Lesions could be pre-treated with any technique or device, such as 
balloon angioplasty, cutting balloon or atherectomy, but implantation 
of SES in each target lesion during the index procedure was manda-
tory. All postoperative medical management, including antithrom-
botic therapy, was prescribed according to usual local practices. The 
protocol was approved by the ethics committee of each participating 
medical centre and the patients granted their consent to participate in 
the registry. Patients for whom the collection of dependable follow-
up information was unlikely and those who received a stent other 
than a CYPHER SES during the index procedure were excluded.
DATA COLLECTION AND MANAGEMENT
The data collected by the e-SELECT registry include demographic 
information, cardiovascular history, comorbidity, lesion and procedure 
characteristics, and antithrombotic regimens. The patients were fol-
lowed at 30, 180 and 360 days by telephone communication, office 
visit, or by contacts with primary physicians or referring cardiologists.
The data were collected electronically at each participating medi-
cal centre and transferred to an independent data management 
organisation (KIKA Medical, Nancy, France). After verification of 
their consistency, the data were analysed by an independent clinical 
research organisation (Cardialysis, Rotterdam, The Netherlands). 
The accuracy of data collection was monitored by an independent 
organisation (Covance, Princeton, NJ, USA) in 20% of the overall 
sample, at 100 centres selected by a stratification scheme based on 
patient enrolment, region of the world and rate of data outliers. The 
consistency and accuracy of data contained in the source documen-
tation versus that entered in the electronic database were verified, 
using an anonymous procedure to preserve confidentiality. The data 
were consistent when present in both the source documents and in 
the electronic database, and accurate when the electronic database 
fully matched the data entered in the source documents. Using these 
definitions, overall data consistency was 99%; the accuracy of 
baseline data was 96%, and that of adverse events recorded during 
follow-up was 93.2%.
ENDPOINTS OF THE E-SELECT REGISTRY
The primary endpoint of the registry was a composite of definite and 
probable ST at one-year follow-up, as defined by the Academic Research 
Consortium (ARC7). The secondary endpoints at one-year included: car-
diac and non-cardiac death, myocardial infarction (MI), and MACE 
(defined as any death, MI or target lesion revascularisation).
STATISTICAL ANALYSIS
For all patients, standard descriptive statistics were used for base-
line, lesion, and procedural characteristics and for clinical results. 
Continuous variables are presented as mean±standard deviations, 
medians and range, and categorical variables such as numbers and 
percentages. Cumulative rates of adverse clinical events were cal-
culated with event-specific adjusted denominators, so that all 
patients experiencing an event within 360 days or followed up for 
at least 330 days after the index procedure contributed to the 
denominator. No missing value imputation was performed. All sta-
tistical analyses were performed with SAS, version 9.1 or higher 
software (SAS Institute, Cary, NC, USA).
Results
A total of 15,147 patients satisfying the inclusion criteria were 
included in the e-SELECT registry. Baseline clinical characteristics 
of patients with multivessel and single-vessel PCI are presented in 
Table 1. Two thousand two hundred and seventy-eight (2,278) sub-
jects (15%) underwent multivessel PCI and 12,869 (85%) had sin-
gle-vessel PCI. In the multivessel PCI group, the mean age was 
higher (63 vs. 62 years, p<0.001), there was a higher prevalence of 
diabetes mellitus (32.4 vs. 30.0%, p=0.02), and the reported prevalence 
of multivessel disease was much higher (98% vs. 36%, p<0.001). 
The single-vessel PCI group had a significantly higher prevalence 
of prior PCI and CABG. The Charlson Comorbidity Index Score 
and the EuroSCORE (standard and logistic) were similar between 
the two groups (Table 1).







TARGET VESSEL AND LESION CHARACTERISTICS
Details regarding the target vessel and lesion characteristics are 
summarised in Table 2. The patients in the multivessel PCI group 
were more likely to undergo treatment of a native artery (99.2 vs. 
97.7%, p<0.001) and the target lesion was less likely to be in-stent 
restenosis (8.0 vs. 13.1%, p<0.001). The subjects in the single-ves-
sel group had more complex lesions reflected by the higher propor-
tion of chronic total occlusions, prevalence of visible thrombus and 
higher rates of B2 and C lesions according to the American Heart 
Association (AHA) classification (Table 2).
PROCEDURAL CHARACTERISTICS
Pre-procedural treatment with aspirin, clopidogrel or ticlopidine 
was more common in the multivessel PCI group than in single-
vessel PCI (90.5 vs. 88.9, p=0.03). The rate of pre-treatment with 
dual antiplatelet therapy was similar between both groups (57.7 vs. 
59%, p=0.28). Figure 1 demonstrates the ratios of pre- and post-
dilatation in the study population. Patients in the multivessel PCI 
group were less likely to undergo predilatation (58.4 vs. 66.5%, 
p<0.001) and also less likely to undergo post-dilatation after stent 
implantation (32.3 vs. 37.5%, p<0.001). Intravascular ultrasound 
(IVUS) use was similar between both groups (3.6 vs. 3.7%, p=0.73). 
Total stent length per patient was markedly longer in the multives-
sel group (57.7 vs. 29.1 mm, p<0.001).
Staged procedures were planned in 6.4% of patients in the multi-
vessel and in 6.5% of the single-vessel PCI patients (p=0.93).
PRINCIPAL EFFECTIVENESS AND SAFETY RESULTS
30-DAY OUTCOMES  Table 3 and Figure 2 summarise the princi-
pal outcomes at 30-days and one-year. There was no significant dif-
ference in the incidence of mortality, cardiac mortality and stent 
thrombosis rates between the multivessel and single-vessel PCI 
group at 30-days. The incidence of myocardial infarction was 
higher in the multivessel PCI group (1.9 vs. 0.8%, p<0.001) and 
most of the infarctions were non-Q-wave MI and related to the pro-
cedure (1.3 vs. 0.6%, p=0.001). The incidence of target vessel 
revascularisation (TVR) was similar between the groups but 
patients in the multivessel PCI group had a higher rate of target 
lesion revascularisation (TLR; 0.7 vs. 0.3%, p=0.027) at 30-days.
360-DAY OUTCOMES  Both overall and cardiac mortality were 
higher in the multivessel PCI group at one-year (Table 3). Most of 
the infarctions were non-Q-wave and related to the procedure 







Age: mean±SD (n) 63.0±10.9 (2,278) 62.0±10.8 (12,867) <0.001
Gender (male) 75.8% (1,727/2,278) 75.3% (9,696/12,869) 0.65
Prior PTCA 27.7% (628/2,269) 32.9% (4,222/12,814) <0.001
Prior CABG 7.8% (176/2,269) 9.3% (1,194/12,814) 0.017
Prior MI 30.8% (700/2,269) 32.4% (4,154/12,814) 0.14
Periph. vascular disease 6.3% (144/2,269) 6.2% (797/12,814) 0.81
Cerebrovascular disease 4.0% (90/2,269) 4.3% (553/12,814) 0.50
Congestive heart failure 3.7% (84/2,269) 4.2% (546/12,814) 0.23
Positive family history 32.6% (739/2,269) 31.7% (4,058/12,814) 0.41
Hypertension 68.8% (1562/2,269) 67.3% (8,609/12,814) 0.13
Hyperlipidaemia 70.3% (1596/2,269) 67.8% (8,693/12,814) 0.019
Current smoker 19.5% (442/2,269) 20.2% (2,588/12,814) 0.44
Pre-procedure creatinine
>2.0 mg/dl 1.8% (36/2,043) 2.8% (315/11,364) 0.008
>3.0 mg/dl 1.0% (21/2,043) 1.7% (191/11,364) 0.027
Diabetes mellitus 32.4% (736/2,269) 30.0% (3,841/12,814) 0.020
Insulin 25.4% (187/736) 27.4% (1,051/3,841) 0.30
Charlson comorbidity index score: mean±SD (n) 1.0±1.2 (2,269) 1.0±1.3 (12,814) 0.73
Standard EuroSCORE: mean±SD (n) 4.9±3.9 (220) 5.4±7.2 (180) 0.32
Logistic EuroSCORE: mean±SD (n) 6.5±9.972 (305) 6.1±7.285 (245) 0.59
LVEF <30% 2.2% (42/1,933) 1.9% (204/10,809) 0.42
Stable angina 40.4% (921/2,278) 41.8% (5,385/12,869) 0.21
ACS 43.5% (991/2,278) 44.1% (5,674/12,869) 0.61
Silent ischaemia 6.0% (137/2,278) 4.4% (565/12,869) <0.001
Asymptomatic 2.3% (53/2,278) 2.4% (314/12,869) 0.82
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(Figure 3). The rate of Q-wave infarctions was not different 
between the two groups and there was no significant difference in 
the TLR, TVR or major bleeding between both groups.
In-hospital MACE (1.6 vs. 0.8%, p<0.001) and one-year MACE 
(6.1 vs. 4.6%, p=0.005) was higher in patients with multivessel 
PCI. Rates of stent thrombosis were higher in the multivessel PCI 
group but the difference did not reach statistical significance.
Discussion
This analysis of the e-SELECT registry demonstrates that despite 
individual lesions having lower complexity, patients undergoing 
multivessel PCI, who were older and had more diffuse coronary 
artery disease (CAD), had higher rates of adverse events. These 
patients had twice as many lesions treated as well as total stented 
length and number of stents implanted. The in-hospital MACE rate 
was higher and this was mainly driven by the incidence of peripro-
cedural MI. At one-year, overall and cardiac mortality and inci-
dence of myocardial infarction were all significantly higher in the 
multivessel PCI group. There was also a trend towards a higher 
incidence of stent thrombosis in the multivessel PCI group, possi-
bly explained by the doubling of the total stent length in this group.









Native coronary artery 99.2% (5,303/5,345) 97.7% (14,261/14,590) <0.001
2-vessel disease 64.4% (1,466/2,278) 21.6% (2,776/12,869) <0.001
3-vessel disease 34.0% (775/2,278) 14.4% (1,852/12,869) <0.001
Left main 3.4% (180/5,303) 1.9% (269/14,261) <0.001
Protected LM 38.2% (65/170) 41.1% (104/253) 0.61
Unprotected LM 61.8% (105/170) 58.9% (149/253) 0.61
Bypass graft 0.8% (42/5,345) 2.3% (329/14,590) <0.001
De novo stenosis 92.0% (4,822/5,242) 86.9% (12,515/14,409) <0.001
Restenosis 8.0% (420/5,242) 13.1% (1,894/14,409) <0.001
Bifurcation requiring double guidewire 11.4% (596/5,242) 12.8% (1,841/14,409) 0.008
Thrombus present 3.3% (155/4,657) 8.6% (1,110/12,979) <0.001
Heavy calcification 3.8% (178/4,706) 4.1% (541/13,074) 0.30
Total occlusion
<3 months 2.4% (126/5,242) 6.4% (925/14,409) <0.001
≥3 months 2.1% (111/5,242) 3.5% (506/14,409) <0.001
unknown duration 2.2% (114/5,242) 3.3% (475/14,409) <0.001
ACC/AHA lesion class
Type A 11.8% (611/5,160) 11.6% (1,653/14,273) 0.61
Type B1 34.8% (1,796/5,160) 30.7% (4,383/14,273) <0.001
Type B2 30.6% (1,581/5,160) 32.7% (4,674/14,273) 0.005
Type C 22.7% (1,172/5,160) 25.0% (3,563/14,273) 0.001
IVUS used 3.6% (187/5,178) 3.7% (526/14,116) 0.73
Treated lesions per patient 2.3±0.6 (2,278) 1.1±0.40 (12,869) <0.001
Stents per patient 2.7±1.0 (2,278) 1.3±0.6 (12,869) <0.001
Stent length per patient 57.7±25.5 (2,212) 29.1±16.6 (12,270) <0.001
Figure 1. Ratios of pre- and post-dilatation in patients with 



















In the e-SELECT registry there was a significant difference in 
the rates of lesion preparation and post-dilatation between the sin-
gle-vessel and multivessel disease groups. Consequently this must 
reflect an increased rate of direct stenting by operators when multi-
ple lesions were treated. Although direct stenting is effective in 
selected lesions8,9 this strategy might not be optimal when lesions 
are more complex and/or calcified. In the e-SELECT population 
only 11.8% of the lesions were Type A and almost one quarter of 






Outcomes at 30 days
Mortality 0.58% (13/2,246) 0.32% (40/12,707) 0.08
Cardiac mortality 0.49% (11/2,244) 0.26% (33/12,701) 0.09
Stent thrombosis 0.8% (18/2,242) 0.54% (69/12,697) 0.13
Myocardial infarction 1.88% (42/2,238) 0.91% (115/12,678) <0.001
Q-wave MI 0.36% (8/2,237) 0.21% (26/12,675) 0.15
Non-Q-wave MI 1.57% (35/2,236) 0.69% (88/12,673) <0.001
Periprocedural MI 1.25% (28/2,236) 0.59% (75/12,671) 0.001
TLR 0.67% (15/2,237) 0.34% (43/12,673) 0.027
TVR 0.72% (16/2,237) 0.44% (56/12,673) 0.1
Major bleeding 0.36% (8/2,235) 0.39% (49/12,670) 1
Outcomes at 1 year
Mortality 2.35% (49/2,083) 1.58% (187/11,828) 0.016
Cardiac mortality 1.45% (30/2,065) 0.9% (106/11,754) 0.029
Stent thrombosis 1.8% (37/2,060) 1.3% (154/11,738) 0.1
Myocardial infarction 2.88% (59/2,051) 1.75% (205/11,688) 0.001
Q-wave MI 0.69% (14/2,044) 0.37% (43/11,667) 0.059
Non-Q-wave MI 2.25% (46/2,046) 1.39% (162/11,676) 0.006
TLR 2.59% (53/2,047) 2.19% (256/11,682) 0.26
TVR 4.2% (86/2,048) 3.09% (361/11,686) 0.012
Major bleeding 0.98% (20/2,041) 0.95% (111/11,667) 0.9
MACE 6.05% (126/2,084) 4.6% (545/11,848) 0.005
MI: myocardial infarction; TLR: target lesion revascularisation; TVR: target vessel revascularisation; MACE: any death, myocardial infarction or TLR








































them were Type C lesions according to the AHA classification10. 
It is possible to speculate that operators were tempted to minimise 
multivessel procedure times by direct stenting at least one target 
lesion.
Although post-dilation with minimally compliant balloons was 
considered routine during the early coronary stent experience, 
improved stent and balloon technology has led to considerable vari-
ation in post-dilation usage in routine contemporary practice. 
Despite these improvements in stent technology, incomplete stent 
expansion remains a predictor of both stent thrombosis and later in-
stent restenosis11,12. Adjunctive balloon post-dilatation does not dis-
tort stent anatomy13 and has the potential to reduce adverse 
outcomes by optimising expansion of drug-eluting stents14. In the 
e-SELECT registry there was a significant difference in the rates of 
post-dilatation between the single-vessel and multivessel disease 
groups. This observation that pre- and post-dilatation were used 
less commonly in the multivessel PCI group could be an important 
factor in the observed increased one-year MACE rates.
In the e-SELECT registry, patients in the multivessel PCI group 
had a higher proportion of myocardial infarctions at 30-days and 
most of these were non-Q-wave infarctions related to the proce-
dure. In-hospital MACE, defined as the composite endpoint of 
death, myocardial infarction and target-lesion revascularisation, 
was higher in the multivessel PCI group.
Periprocedural myocardial infarction is an important prognostic 
marker following PCI15,16. Distal embolisation and side branch 
occlusion are known to be contributing factors and the risk of myo-
cardial injury during PCI increases with lesion complexity reflected 
by the SYNTAX score15. One might assume that patients with more 
atheroma might be at higher procedural risk and this might in itself 
explain the higher incidence of procedural infarction. However this 
explanation does not appear to be applicable, as the multivessel 
group had less complex lesions (according to the AHA classifica-
tion10) and less high-risk clinical features17 (higher rates of prior 
CABG, severe renal failure, bypass grafts and in-stent restenosis). 
Alternatively one could assume that when treating longer lengths of 
atheroma in the same sitting, enzyme release will increase in 
a cumulative fashion. This explanation appears to be more plausi-
ble, bringing to question the rationale for systematically treating 
multiple non-complex lesions during the same procedure when it 
may not always be clinically indicated. Notably, recruitment to 
e-SELECT predated the publication of the FAME study18 and it is 
possible that increased use of fractional flow reserve measurement 
might have resulted in less stent implantation, reduced periproce-
dural injury, and might potentially have been associated with 
greater clinical benefit.
Limitations
It is important to mention some limitations of this study. These are 
registry data of selected patients who underwent a successful proce-
dure with only SES at index.
There was probably a selection bias as it can be assumed that the 
second or third vessel in the multivessel procedures were only 
approached after the first lesion was successfully treated. This is 
supported by the fact that there were more complex lesions in the 
single-vessel group.
Patients undergoing multivessel PCI more often had multivessel 
disease than the single-vessel PCI, somewhat limiting the compari-
son between the two groups.
The patients with acute ST-elevation myocardial infarction most 
often only received treatment of the culprit lesion: they would more 
often have been in the single-vessel group, and were known to have 
a higher ST risk. Additionally there were more saphenous vein 
grafts (SVG) treated in the single-vessel group.
No recommendations were made for biomarker measurements 
post-procedure: periprocedural MI were most probably underesti-
mated in both groups.
Conclusions
In this registry, multivessel PCI was associated with higher rates of 
periprocedural myocardial infarction when compared to single-
vessel PCI. Additionally, rates of overall death, cardiac death and 
non-Q-wave infarctions were higher in the multivessel PCI group. 
Patients treated in the multivessel PCI group had lower rates of pre- 
and post-dilatation and this could have contributed to the increased 
rate of sub-optimal outcomes. The results of our study suggest that 
multivessel PCI in a single sitting should be the exception rather 
than the rule in patients needing treatment in more than one coro-
nary artery.
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